Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Know how to frame the request
In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study ( With these points in mind, we undertook a broad assessment of published clinical data, curating the body weight loss (% from baseline), glycosylated hemoglobin levels (HbA1c), and nausea responses (% patients reporting) from the SUSTAIN 3, SUSTAIN 7, SCALE Diabetes, SURPASS 2, and STEP 2 trials ( Figures 1AC )
Because treatment typically begins with a lower dose, the body has time to adapt safely
Bring this log to every follow-up your prescriber will use the trend, not a single reading, to decide whether to hold the current dose or titrate up
^ Glucagon-Like Peptides: Advances in Research and Application
US$ 20.07
US$ 26.26
US$ 24.60
US$ 26.72
